Increased adiponectin associated with poor survival in hepatocellular carcinoma

Journal of Gastroenterology

Volumn 49, Issue 9, 2014, Pages 1342-1351

  Wang, Shen Nien ^a   Yang, Sheau Fang ^b   Tsai, Hsin Hui ^a,c   Lee, King Teh ^a   Yeh, Yao Tsung ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^c FOOYIN UNIVERSITY   (Taiwan)

Author keywords

Adiponectin; Adiponectin receptor; AKT; Hepatocellular carcinoma; Immunohistochemistry

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADIPONECTIN; CYCLIN D1; NEUTRALIZING ANTIBODY; STAT3 PROTEIN; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; BRDU ASSAY; CANCER SURVIVAL; CELL CULTURE; CELL GROWTH; CELL INVASION ASSAY; CELL PROLIFERATION ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEPG2 CELL LINE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TUMOR CELL LINE; VERY ELDERLY;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL RATE;

EID: 84920720160     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0898-7     Document Type: Article

References (34)

1. Gil-Campos M, Canete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr. 2004;23(5):963-74.
2. Anania FA. Adiponectin and alcoholic fatty liver: is it, after all, about what you eat? Hepatology. 2005;42(3):530-2.
3. Neumeier M, Weigert J, Schcaffler A, Wehrwein G, Muller-Ladner U, Scholmerich J, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 2006;79(4): 803-8.
4. Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology. 2007;148(11):5478-86.
5. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(9):1198-201.
6. Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. Am J Physiol Endocrinol Metab. 2006;290(2):E326-33.
7. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13(1):134-41.
8. Liu CJ, Chen PJ, Lai MY, Liu CH, Chen CL, Kao JH, et al. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hep Intl. 2009;3(2):364-70.
9. Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer. 2011;129(9):2226-35.
10. Chen MJ, Yeh YT, Lee KT, Tsai CJ, Lee HH, Wang SN. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol. 2012;106(2):181-7.
11. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762-9.
12. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, et al. Adiponectin stimulates angiogenesis by promoting crosstalk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem. 2004;279(2):1304-9.
13. Ogunwobi OO, Beales IL. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept. 2006;134(2-3):105-13.
14. Barb D, Neuwirth A, Mantzoros CS, Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 2007;14(4):995-1005.
15. The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg. 1989; 19(1):98-129.
16. Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC, et al. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol. 2007;60(6):642-8.
17. Wang SN, Yeh YT, Yang SF, Chai CY, Lee KT. Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol. 2006;59(9):930-4.
18. Yuan SS, Cox LA, Dasika GK, Lee EY. Cloning and functional studies of a novel gene aberrantly expressed in RB-deficient embryos. Dev Biol. 1999;207(1):62-75.
19. Chang HL, Su JH, Yeh YT, Lee YC, Chen HM, Wu YC, et al. Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo. Cancer Lett. 2008;267(1):85-95.
20. Lin SY, Liu JD, Chang HC, Yeh SD, Lin CH, Lee WS. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem. 2002;84(3):532-44.
21. Yang L, Chan CC, Kwon OS, Liu S, McGhee J, Stimpson SA, et al. Regulation of peroxisome proliferator-activated receptorgamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2006;291(5):G902-11.
22. Bogan JS, Lodish HF. Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol. 1999;146(3):609-20.
23. Wang SN, Yeh YT, Yu ML, Wang CL, Lee KT. Serum adiponectin levels in cholesterol and pigment cholelithiasis. Br J Surg. 2006;93(8):981-6.
24. Yeh YT, Ou-Yang F, Chen IF, Yang SF, Su JH, Hou MF, et al. Altered p-JAK1 expression is associated with estrogen receptor status in breast infiltrating ductal carcinoma. Oncol Rep. 2007;17(1):35-9.
25. Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC, et al. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol. 2007;60(6):642-8.
26. El-Serag HB, Rudolph L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7): 2557-76.
27. Sumie S, Kawaguchi T, Kuromatsu R, Takata A, Nakano M, Satani M, et al. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS One. 2011;6(11):e26840.
28. Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology. 2010; 139(5):1762-73, 1773 e1-5.
29. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010;52(5):1713-22.
30. Ogunwobi OO, Beales ILP. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept. 2006;134(2-3):105-13.
31. Perez-Tenorio G, Stal O, Group SSBC. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer. 2002;86(4):540-5.
32. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10(8):2846-50.
33. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008;48(1):83-90.
34. He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA, et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet. 2007;39(2):189-98.